Mifegyne

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as a tablet for oral use. It is employed in the medical termination of intrauterine pregnancy up to 9 weeks gestation, providing a non‑surgical option for eligible women.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from transparent pricing, regulatory support, and consistent product availability across diverse markets.

Mifegyne (mifepristone) is a progesterone receptor antagonist used in early pregnancy termination. - Medical termination of intrauterine pregnancy up to 9 weeks gestation: induces decidual breakdown and facilitates expulsion of the gestational sac. - Pre‑treatment before misoprostol administration: sensitizes the uterus to prostaglandins, improving the efficacy of subsequent medication. - Adjunct in management of early pregnancy loss: supports medical evacuation when combined with prostaglandins.

Mifegyne may cause a range of adverse reactions, most of which are mild and self‑limiting.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Abdominal pain or cramping: uterine contractions causing discomfort. - Vaginal bleeding: spotting or heavier flow. - Fatigue: temporary loss of energy. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe infection: signs of fever or sepsis require urgent care. - Heavy hemorrhage: excessive bleeding may need surgical intervention. - Allergic reaction (anaphylaxis): rapid swelling, breathing difficulty, or rash. - Incomplete abortion: retained tissue requiring further treatment. - Liver dysfunction: abnormal liver enzymes or jaundice.

Before prescribing Mifegyne, clinicians should observe several safety measures. - Confirm gestational age: ensure pregnancy is ≤9 weeks by ultrasound. - Obtain informed consent: discuss risks, benefits, and alternatives with the patient. - Screen for contraindications: chronic adrenal insufficiency, long‑term corticosteroid therapy, or anticoagulant use. - Monitor vital signs: watch for excessive bleeding or signs of infection. - Provide follow‑up care: schedule post‑treatment assessment to confirm complete evacuation. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Mifegyne can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce mifepristone effectiveness. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Long‑acting corticosteroids: may mask adrenal insufficiency.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal discomfort. - Antibiotics such as metronidazole: limited data, monitor clinical response. - Antifungal azoles: potential pharmacokinetic interaction, observe for altered drug levels.